生物质碳材料的孔道类型和孔径大小制约着材料有效的活性位点数量,影响材料的性能。孔道分类又是孔径分析的前提条件,因此,建立孔道分类的方法非常有意义。随着生物质碳材料的深入研究,研究者对其孔道分析的要求逐渐提高。由于实际的吸...生物质碳材料的孔道类型和孔径大小制约着材料有效的活性位点数量,影响材料的性能。孔道分类又是孔径分析的前提条件,因此,建立孔道分类的方法非常有意义。随着生物质碳材料的深入研究,研究者对其孔道分析的要求逐渐提高。由于实际的吸脱附等温线具有不规则性,难以匹配IUPAC规范中的吸脱附等温线,所以,用实际的吸脱附等温线与IUPAC规范中的吸脱附等温线进行匹配对生物质碳材料的孔道进行分类准确度不能得到保证。使用自制生物质碳材料,运用物理吸附仪对其进行表征,采用BET方程(Brunauer-Emmett-Teller)、T-plot方法(Thickness-plot)、DFT方法(Non-local Density Functional Theory)、BJH(Barrett Joyner And Halenda)方法对其孔道进行分析。研究表明,采用孔隙率和比表面积占有率对其进行孔道分类,可以准确地定义出微孔生物质碳材料、介孔生物质碳材料和微介孔生物质碳材料,从而建立了孔隙率和比表面积占有率的孔道分类新方法。用标准样品对孔隙率和比表面积占有率的孔道分类新方法进行论证,结果一致。方法准确可靠、实用性高。展开更多
Objective： To investigate the expressions of GSK-3beta, Beta-catenin and PPAR-gamma, and their relationship in medulloblastoma, and to explore their value in clinic application. Methods： Immunohistochemical stainin...Objective： To investigate the expressions of GSK-3beta, Beta-catenin and PPAR-gamma, and their relationship in medulloblastoma, and to explore their value in clinic application. Methods： Immunohistochemical staining with SP method was conducted to determine the expressions of GSK-3beta, Beta-catenin and PPAR-gamma in 48 cases of medulloblastoma and 10 normal cerebellar tissues. Results： The rate of abnormal expressions of beta-catenin and PPAR-gamma in MB was higher than that in normal. Conversely, GSK-3beta in MB was lower than that in the normal （P〈0.05）. Furthermore, in medulloblastoma, beta-catenin and GSK-3beta showed a negative correlation, PPAR-gamma and beta-catenin had a positive correlation. Conclusion： Abnormal expression of beta-catenin plays a crucial role in the development of medulloblastoma. Meanwhile, PPAR-gamma and GSK-3beta which are tightly related with beta-catenin are both involved in the genesis and development of medulloblastoma.展开更多
Several studies have demonstrated that the amount of beta-amyloid （Aβ） protein in the brain can be lowered by down-regulating Aβ production, promoting Aβ degradation, reducing Aβ oligomerization or deposition, ...Several studies have demonstrated that the amount of beta-amyloid （Aβ） protein in the brain can be lowered by down-regulating Aβ production, promoting Aβ degradation, reducing Aβ oligomerization or deposition, thereby alleviating symptoms of Alzheimer＇s disease. Curcumin has been known to be a peroxisome proliferator activated receptor gamma （PPARy） agonist and can obviously inhibit Aβ production and oligomerization. This study investigated the effects of curcumin on the G-site APP cleaving enzyme 1 （BACE1） activity and PPARy expression in human neuroblastoma SH-SY5Y cells, and validated the inhibitory effects of curcumin on Aβ40/42 expression in the brain. Results revealed that PPARy mRNA and protein expression in the human neuroblastoma SH-SY5Y cells significantly increased with increasing curcumin concentration and time course （P 〈 0.05）; BACE1 mRNA and protein expression and Aβ40/42 production significantly decreased with increasing curcumin concentration and time course （P 〈 0.05）. The changes in PPARy and BACE1 expression during Aβ production could be reversed by the PPARy antagonist GW9662. These findings indicate that curcumin reduced Aβ production by activating PPARy expression and inhibiting BACE1 expression in a concentration- and time-dependent manner.展开更多
Melanoma remains a rare malignant tumor with high mortality and increasing incidence in China. Due to ethnic characteristics, acral and mucosal melanomas are the predominant subtypes in Asia, many research advances ha...Melanoma remains a rare malignant tumor with high mortality and increasing incidence in China. Due to ethnic characteristics, acral and mucosal melanomas are the predominant subtypes in Asia, many research advances have been made in melanoma these years, especially for these two subtypes. In keeping with the development of key research on melanoma.展开更多
实验室比对盲样测定是检验实验室能力验证、实验室资质认定、机构考核的主要手段。土壤金属元素污染情况是第三次全国土壤普查的一个重要理化指标,为研究并解决测试实验室比对土壤盲样中铍、钒、镍、铜、锌、镉、铅的含量,采用微波消解...实验室比对盲样测定是检验实验室能力验证、实验室资质认定、机构考核的主要手段。土壤金属元素污染情况是第三次全国土壤普查的一个重要理化指标,为研究并解决测试实验室比对土壤盲样中铍、钒、镍、铜、锌、镉、铅的含量,采用微波消解-电感耦合等离子体质谱(ICP-MS)法对土壤盲样进行研究,对不同消解酸体系、检出限和定量限、测试模式和干扰消除、精密度和加标回收率、质控样品进行了探讨,并与电感耦合等离子体发射光谱(ICP-OES)法进行测试结果比对。结果表明:用6 mL HNO_(3)、2 mL HCl和1 mL HF为混合酸体系,各待测元素标准曲线相关系数大于0.999 5、检出限在0.001~3.0μg/L、定量限在0.003~9.9μg/L,采用氦气碰撞模式测试钒、镍、铜、锌、镉和铅,可以有效地降低多原子离子的干扰;采用no gas模式测试铍,可以有效地提高铍的测试灵敏度。方法精密度为0.2%~6.2%(n=6),加标回收率为92.3%~111%,采用土壤标准样品(GSS-4)进行全过程消解测试质控研究分析,各元素结果均在标准值参考范围内。用ICP-OES法测试土壤盲样中7种待测金属元素含量与用铑为内标的ICP-MS法测定值进行比对,ICP-MS法和ICP-OES法测试的各元素的相对标准偏差分别为0.60%~2.2%和0.70%~3.2%,测量结果基本一致。展开更多
Mucosal melanoma(MM)is extremely rare in Caucasians,whereas it is the second predominant melanoma subtype in Asian and other non-Caucasian populations.Distinct from cutaneous melanoma in terms of epidemiology,biology,...Mucosal melanoma(MM)is extremely rare in Caucasians,whereas it is the second predominant melanoma subtype in Asian and other non-Caucasian populations.Distinct from cutaneous melanoma in terms of epidemiology,biology,and molecular characteristics,MM is characterized by more aggressive biological behavior,lower mutational burden,more chromosomal structure variants,and poorer prognosis.Because of the rarity of MM,its biological features are not fully understood,and potential novel therapies are less well depicted.Whereas immunotherapy has shown encouraging efficacy for cutaneous melanoma,its efficacy in MM is unclear due to limited sample sizes in clinical trials.Thus,in this review,we describe the epidemiological,clinical,and molecular features of MM and summarize the efficacies of different immunotherapies for MM,including immune checkpoint inhibitors,vaccines,oncolytic virus therapy,adoptive T-cell therapy,and various combination therapies.展开更多
Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an un...Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an underlying visceral carcinoma(secondary EMPD).Approximately half of EMPD cases are confined to the epidermis,which was defined as intraepithelial EMPD.展开更多
IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced m...IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma(UC).Patients in phase 1a received IBI310 at 0.3/1/2/3 mg/kg intravenously(IV)every 3 weeks(Q3W)following the accelerated titration and 3+3 escalation design.Patients in phase 1b received IBI310(1/2/3 mg/kg IV,Q3W)plus sintilimab(200 mg IV,Q3W)for four cycles,followed by sintilimab maintenance therapy.The phase 1b expansion of IBI310 plus sintilimab was performed in patients with advanced melanoma or UC.Overall,53 patients were enrolled,including 10 patients with melanoma in phase 1a,34 with melanoma,and 9 with UC in phase 1b.Overall,94.3%of patients(50/53)experienced at least one treatment-related adverse event(TRAE)with most being grade 1–2;26.4%of patients(14/53)experienced grade 3 or higher TRAEs.In phase 1a,the disease control rate(DCR)was 50.0%(95%confidence interval[CI],18.7%–81.3%).In phase 1b,the objective response rate(ORR)and DCR were 17.6%(95%CI,6.8%–34.5%)and 44.1%(95%CI,27.2%–62.1%),respectively,for melanoma,and were 22.2%(95%CI,2.8%–60.0%)and 66.7%(95%CI,29.9%–92.5%),respectively,for UC.IBI310 monotherapy or combination therapy with sintilimab was well tolerated with favorable antitumor activity across patients with advanced melanoma and UC.展开更多
中国首个原发研制抗程序性死亡受体1(programmed cell death protein 1,PD-1)抗体特瑞普利单抗(toripalimab)于2018年12月27日获得中国国家食品药品监督管理总局(CFDA)审批,用于标准治疗失败的晚期黑色素瘤的治疗。从Ⅰ期临床试验开展...中国首个原发研制抗程序性死亡受体1(programmed cell death protein 1,PD-1)抗体特瑞普利单抗(toripalimab)于2018年12月27日获得中国国家食品药品监督管理总局(CFDA)审批,用于标准治疗失败的晚期黑色素瘤的治疗。从Ⅰ期临床试验开展到最终上市,前后历经3年的时间。这是中国生物制药领域的突破,为中国医药自主研发在肿瘤免疫治疗领域奠定了基础。本文对特瑞普利单抗在黑色素瘤治疗领域的相关临床研究予以总结,并结合国际上抗PD-1抗体在黑色素瘤研发领域的发展,分析特瑞普利单抗的研发前景,以期指导中国黑色素瘤的诊治。展开更多
文摘生物质碳材料的孔道类型和孔径大小制约着材料有效的活性位点数量,影响材料的性能。孔道分类又是孔径分析的前提条件,因此,建立孔道分类的方法非常有意义。随着生物质碳材料的深入研究,研究者对其孔道分析的要求逐渐提高。由于实际的吸脱附等温线具有不规则性,难以匹配IUPAC规范中的吸脱附等温线,所以,用实际的吸脱附等温线与IUPAC规范中的吸脱附等温线进行匹配对生物质碳材料的孔道进行分类准确度不能得到保证。使用自制生物质碳材料,运用物理吸附仪对其进行表征,采用BET方程(Brunauer-Emmett-Teller)、T-plot方法(Thickness-plot)、DFT方法(Non-local Density Functional Theory)、BJH(Barrett Joyner And Halenda)方法对其孔道进行分析。研究表明,采用孔隙率和比表面积占有率对其进行孔道分类,可以准确地定义出微孔生物质碳材料、介孔生物质碳材料和微介孔生物质碳材料,从而建立了孔隙率和比表面积占有率的孔道分类新方法。用标准样品对孔隙率和比表面积占有率的孔道分类新方法进行论证,结果一致。方法准确可靠、实用性高。
文摘Objective： To investigate the expressions of GSK-3beta, Beta-catenin and PPAR-gamma, and their relationship in medulloblastoma, and to explore their value in clinic application. Methods： Immunohistochemical staining with SP method was conducted to determine the expressions of GSK-3beta, Beta-catenin and PPAR-gamma in 48 cases of medulloblastoma and 10 normal cerebellar tissues. Results： The rate of abnormal expressions of beta-catenin and PPAR-gamma in MB was higher than that in normal. Conversely, GSK-3beta in MB was lower than that in the normal （P〈0.05）. Furthermore, in medulloblastoma, beta-catenin and GSK-3beta showed a negative correlation, PPAR-gamma and beta-catenin had a positive correlation. Conclusion： Abnormal expression of beta-catenin plays a crucial role in the development of medulloblastoma. Meanwhile, PPAR-gamma and GSK-3beta which are tightly related with beta-catenin are both involved in the genesis and development of medulloblastoma.
基金the National Natural Science Foundation of China,No.30600196the Science Foundation of Chongqing,No.2006BB5042the Scientific Research Foundation for the Returned Overseas Chinese Scholars,State Education Ministry,No.[2007]1108
文摘Several studies have demonstrated that the amount of beta-amyloid （Aβ） protein in the brain can be lowered by down-regulating Aβ production, promoting Aβ degradation, reducing Aβ oligomerization or deposition, thereby alleviating symptoms of Alzheimer＇s disease. Curcumin has been known to be a peroxisome proliferator activated receptor gamma （PPARy） agonist and can obviously inhibit Aβ production and oligomerization. This study investigated the effects of curcumin on the G-site APP cleaving enzyme 1 （BACE1） activity and PPARy expression in human neuroblastoma SH-SY5Y cells, and validated the inhibitory effects of curcumin on Aβ40/42 expression in the brain. Results revealed that PPARy mRNA and protein expression in the human neuroblastoma SH-SY5Y cells significantly increased with increasing curcumin concentration and time course （P 〈 0.05）; BACE1 mRNA and protein expression and Aβ40/42 production significantly decreased with increasing curcumin concentration and time course （P 〈 0.05）. The changes in PPARy and BACE1 expression during Aβ production could be reversed by the PPARy antagonist GW9662. These findings indicate that curcumin reduced Aβ production by activating PPARy expression and inhibiting BACE1 expression in a concentration- and time-dependent manner.
文摘Melanoma remains a rare malignant tumor with high mortality and increasing incidence in China. Due to ethnic characteristics, acral and mucosal melanomas are the predominant subtypes in Asia, many research advances have been made in melanoma these years, especially for these two subtypes. In keeping with the development of key research on melanoma.
文摘实验室比对盲样测定是检验实验室能力验证、实验室资质认定、机构考核的主要手段。土壤金属元素污染情况是第三次全国土壤普查的一个重要理化指标,为研究并解决测试实验室比对土壤盲样中铍、钒、镍、铜、锌、镉、铅的含量,采用微波消解-电感耦合等离子体质谱(ICP-MS)法对土壤盲样进行研究,对不同消解酸体系、检出限和定量限、测试模式和干扰消除、精密度和加标回收率、质控样品进行了探讨,并与电感耦合等离子体发射光谱(ICP-OES)法进行测试结果比对。结果表明:用6 mL HNO_(3)、2 mL HCl和1 mL HF为混合酸体系,各待测元素标准曲线相关系数大于0.999 5、检出限在0.001~3.0μg/L、定量限在0.003~9.9μg/L,采用氦气碰撞模式测试钒、镍、铜、锌、镉和铅,可以有效地降低多原子离子的干扰;采用no gas模式测试铍,可以有效地提高铍的测试灵敏度。方法精密度为0.2%~6.2%(n=6),加标回收率为92.3%~111%,采用土壤标准样品(GSS-4)进行全过程消解测试质控研究分析,各元素结果均在标准值参考范围内。用ICP-OES法测试土壤盲样中7种待测金属元素含量与用铑为内标的ICP-MS法测定值进行比对,ICP-MS法和ICP-OES法测试的各元素的相对标准偏差分别为0.60%~2.2%和0.70%~3.2%,测量结果基本一致。
基金supported by the National Natural Science Foundation of China(82272676,82073011,81972562,81972566)Beijing Medical Award Foundation(YXJL-2020-0889-0106)+1 种基金Beijing Municipal Administration of Hospitals'Ascent Plan(DFL20220901)Beijing Xisike Clinical Oncology Research Foundation(Y-Roche2019/2-0076).
文摘Mucosal melanoma(MM)is extremely rare in Caucasians,whereas it is the second predominant melanoma subtype in Asian and other non-Caucasian populations.Distinct from cutaneous melanoma in terms of epidemiology,biology,and molecular characteristics,MM is characterized by more aggressive biological behavior,lower mutational burden,more chromosomal structure variants,and poorer prognosis.Because of the rarity of MM,its biological features are not fully understood,and potential novel therapies are less well depicted.Whereas immunotherapy has shown encouraging efficacy for cutaneous melanoma,its efficacy in MM is unclear due to limited sample sizes in clinical trials.Thus,in this review,we describe the epidemiological,clinical,and molecular features of MM and summarize the efficacies of different immunotherapies for MM,including immune checkpoint inhibitors,vaccines,oncolytic virus therapy,adoptive T-cell therapy,and various combination therapies.
基金supported by Beijing Medical Award Foundation(No.YXJL-2020-0889-0106)Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20220901)Beijing Xisike Clinical Oncology Research Foundation(Nos.Y-Roche2019/2-0076 and Y-SY201901-0270).
文摘Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an underlying visceral carcinoma(secondary EMPD).Approximately half of EMPD cases are confined to the epidermis,which was defined as intraepithelial EMPD.
基金supported by grants from Beijing Health Technologies Promotion Program(BHTPP2022041)Peking University Clinical Scientist Training Program,the Fundamental Research Funds for the Central Universities(BMU2024PYJH010)+2 种基金Beijing Municipal Administration of Hospitals Incubating Program(PX2021046)Science Foundation of Peking University Cancer Hospital(PY202333)Innovent Biologics,Inc.,Suzhou,China.The funder,Innovent Biologics,was involved in the study design,data collection,data analysis,and data interpretation.
文摘IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma(UC).Patients in phase 1a received IBI310 at 0.3/1/2/3 mg/kg intravenously(IV)every 3 weeks(Q3W)following the accelerated titration and 3+3 escalation design.Patients in phase 1b received IBI310(1/2/3 mg/kg IV,Q3W)plus sintilimab(200 mg IV,Q3W)for four cycles,followed by sintilimab maintenance therapy.The phase 1b expansion of IBI310 plus sintilimab was performed in patients with advanced melanoma or UC.Overall,53 patients were enrolled,including 10 patients with melanoma in phase 1a,34 with melanoma,and 9 with UC in phase 1b.Overall,94.3%of patients(50/53)experienced at least one treatment-related adverse event(TRAE)with most being grade 1–2;26.4%of patients(14/53)experienced grade 3 or higher TRAEs.In phase 1a,the disease control rate(DCR)was 50.0%(95%confidence interval[CI],18.7%–81.3%).In phase 1b,the objective response rate(ORR)and DCR were 17.6%(95%CI,6.8%–34.5%)and 44.1%(95%CI,27.2%–62.1%),respectively,for melanoma,and were 22.2%(95%CI,2.8%–60.0%)and 66.7%(95%CI,29.9%–92.5%),respectively,for UC.IBI310 monotherapy or combination therapy with sintilimab was well tolerated with favorable antitumor activity across patients with advanced melanoma and UC.
文摘中国首个原发研制抗程序性死亡受体1(programmed cell death protein 1,PD-1)抗体特瑞普利单抗(toripalimab)于2018年12月27日获得中国国家食品药品监督管理总局(CFDA)审批,用于标准治疗失败的晚期黑色素瘤的治疗。从Ⅰ期临床试验开展到最终上市,前后历经3年的时间。这是中国生物制药领域的突破,为中国医药自主研发在肿瘤免疫治疗领域奠定了基础。本文对特瑞普利单抗在黑色素瘤治疗领域的相关临床研究予以总结,并结合国际上抗PD-1抗体在黑色素瘤研发领域的发展,分析特瑞普利单抗的研发前景,以期指导中国黑色素瘤的诊治。
